v3.26.1
SEGMENT INFORMATION (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment 1   1  
Number of reportable segments | segment 1   1  
Segment Reporting Information [Line Items]        
Royalty revenues $ 86 $ 202 $ 570 $ 501
Operating expenses        
Research and development 817 6,124 19,237 30,946
General and administrative 3,085 3,275 11,082 13,192
Operating loss (3,816) (9,197) (29,749) (43,637)
Income tax expense 0 0 4 4
Loss from continuing operations (3,585) (8,603) (26,736) (39,807)
Net loss (3,585) (8,611) (26,483) (39,834)
Reportable Segment        
Operating expenses        
Research and development     2,994 3,413
General and administrative 3,085 3,275 11,082 13,192
Total operating expenses 3,902 9,399 30,319 44,138
Operating loss (3,816) (9,197) (29,749) (43,637)
Other income, net 231 594 3,017 3,834
Loss from continuing operations before income taxes (3,585) (8,603) (26,732) (39,803)
Income tax expense 0 0 4 4
Loss from continuing operations (3,585) (8,603) (26,736) (39,807)
Income (loss) from discontinued operations, net of income taxes 0 (8) 253 (27)
Net loss (3,585) (8,611) (26,483) (39,834)
Reportable Segment | Royalty revenues        
Segment Reporting Information [Line Items]        
Royalty revenues 86 202 570 501
Reportable Segment | Repibresib (VYN201)        
Operating expenses        
Research and development 150 2,577 8,487 16,271
Reportable Segment | VYN202        
Operating expenses        
Research and development $ 194 $ 2,521 $ 7,756 $ 11,262